CD79B and cancer: Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate (ADC) that preferentially delivers a potent anti-mitotic agent, monomethyl auristatin E (MMAE) (4), to B cells, which results in anti-cancer activity against B-cell malignancies (5).